Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–86.
Li X, Chen R, Tu YR, Lin M, Lai FC, Li YP, et al. Epidemiological survey of primary palmar hyperhidrosis in adolescents. Chin Med J (Engl). 2007;120(24):2215–7.
Tu YR, Li X, Lin M, Lai FC, Li YP, Chen JF, et al. Epidemiological survey of primary palmar hyperhidrosis in adolescent in Fuzhou of People’s Republic of China. Eur J Cardiothorac Surg. 2007;31(4):737–9.
Gross KM, Schote AB, Schneider KK, Schulz A, Meyer J. Elevated social stress levels and depressive symptoms in primary hyperhidrosis. PLoS One. 2014;9(3): e92412.
PubMed PubMed Central Article CAS Google Scholar
Henning MAS, Ibler KS, Loft I, Ostrowski SR, Erikstrup C, Nielsen KR, et al. The health-related quality of life in hyperhidrosis and co-morbidities. Qual Life Res; 2022.
Deckers IE, Kimball AB. The handicap of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):17–22.
CAS PubMed Article Google Scholar
Kristensen JK, Grejsen D, Swartling C, Bygum A. In hyperhidrosis quality of life is even worse than in acne, eczema, or psoriasis. A comparison of Skindex-16 and Dermatology Life Quality Index (DLQI). Int J Dermatol. 2020.
Shayesteh A, Janlert U, Nylander E. Hyperhidrosis—sweating sites matter: quality of life in primary hyperhidrosis according to the sweating sites measured by SF-36. Dermatology. 2017;233(6):441–5.
Henning MAS, Ibler KS, Ostrowski SR, Erikstrup C, Nielsen KR, Bruun MT, et al. Hyperhidrosis and the risk of being treated for skin infections. J Dermatol Treat. 2021:1–7.
Lessa Lda R, Luz FB, De Rezende RM, Duraes SM, Harrison BJ, De Menezes GB, et al. The psychiatric facet of hyperhidrosis: demographics, disability, quality of life, and associated psychopathology. J Psychiatr Pract. 2014;20(4):316–23.
Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee TK, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol. 2016;75(6):1126–33.
Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case–control study of 387 patients. J Am Acad Dermatol. 2009;61(2):242–6.
Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743–9.
PubMed PubMed Central Article Google Scholar
Obed D, Salim M, Bingoel AS, Hofmann TR, Vogt PM, Krezdorn N. Botulinum toxin versus placebo: a meta-analysis of treatment and quality-of-life outcomes for hyperhidrosis. Aesthetic Plast Surg. 2021;45(4):1783–91.
PubMed PubMed Central Article Google Scholar
Parrish C, Waldbaum B, Coleman D, Blevins C, Rodgers K, Lee B, et al. Microwave thermolysis reduces generalized and social anxiety in young adults with axillary hyperhidrosis. Lasers Surg Med. 2020;52(9):842–7.
Hu Y, Converse C, Lyons MC, Hsu WH. Neural control of sweat secretion: a review. Br J Dermatol. 2018;178(6):1246–56.
CAS PubMed Article Google Scholar
Wade R, Llewellyn A, Jones-Diette J, Wright K, Rice S, Layton AM, et al. Interventional management of hyperhidrosis in secondary care: a systematic review. Br J Dermatol. 2018;179(3):599–608.
CAS PubMed Article Google Scholar
Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 Phase III randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135–45.
Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128-38.e2.
CAS PubMed Article Google Scholar
Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, et al. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(8):1149–61.
CAS PubMed PubMed Central Article Google Scholar
Gregoriou S, Sidiropoulou P, Kontochristopoulos G, Rigopoulos D. Management strategies of palmar hyperhidrosis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:733–44.
CAS PubMed PubMed Central Article Google Scholar
Lueangarun S, Sermsilp C, Tempark T. Topical botulinum toxin type A liposomal cream for primary axillary hyperhidrosis: a double-blind, randomized, split-site, vehicle-controlled study. Dermatol Surg. 2018;44(8):1094–101.
CAS PubMed Article Google Scholar
Glaser DA, Coleman WP 3rd, Fan LK, Kaminer MS, Kilmer SL, Nossa R, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg. 2012;38(2):185–91.
CAS PubMed Article Google Scholar
Leclère FM, Moreno-Moraga J, Alcolea JM, Vogt PM, Royo J, Cornejo P, et al. Efficacy and safety of laser therapy on axillary hyperhidrosis after one year follow-up: a randomized blinded controlled trial. Lasers Surg Med. 2015;47(2):173–9.
Letada PR, Landers JT, Uebelhoer NS, Shumaker PR. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol. 2012;11(1):59–63.
Fatemi Naeini F, Abtahi-Naeini B, Pourazizi M, Nilforoushzadeh MA, Mirmohammadkhani M. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: a sham control study. Australas J Dermatol. 2015;56(4):279–84.
Swaile DF, Elstun LT, Benzing KW. Clinical studies of sweat rate reduction by an over-the-counter soft-solid antiperspirant and comparison with a prescription antiperspirant product in male panelists. Br J Dermatol. 2012;166(Suppl 1):22–6.
Thianboonsong T, Kanokrungsee S, Paichitrojjana A, Udompataikul M, Kamanamool N, Rojhirunsakool S. Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: a randomized controlled trial. Dermatol Ther. 2020;33(6): e14354.
CAS PubMed Article Google Scholar
Streker M, Reuther T, Verst S, Kerscher M. Axillary hyperhidrosis–efficacy and tolerability of an aluminium chloride antiperspirant. Prospective evaluation on 20 patients with idiopathic axillary hyperhidrosis. Hautarzt. 2010;61(2):139–44.
CAS PubMed Article Google Scholar
Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. J Drugs Dermatol. 2009;8(5):477–80.
Streker M, Reuther T, Hagen L, Kerscher M. Hyperhidrosis plantaris—a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminium chloride. J Dtsch Dermatol Ges. 2012;10(2):115–9.
Masur C, Soeberdt M, Kilic A, Knie U, Abels C. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2020;182(1):229–31.
Abels C, Soeberdt M, Kilic A, Reich H, Knie U, Jourdan C, et al. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol. 2021;185(2):315–22.
CAS PubMed PubMed Central Article Google Scholar
Hyun MY, Son IP, Lee Y, Choi HG, Park KY, Li K, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol. 2015;29(2):278–82.
CAS PubMed Article Google Scholar
Hebert AA, Glaser DA, Green L, Werschler WP, Forsha DW, Drew J, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Pediatr Dermatol. 2019;36(1):89–99.
Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593–604.
PubMed PubMed Central Article Google Scholar
Hebert AA, Glaser DA, Green L, Hull C, Cather J, Drew J, et al. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analysis from a 44-week open-label extension study. Pediatr Dermatol. 2020;37(3):490–7.
PubMed PubMed Central Article Google Scholar
Yokozeki H, Fujimoto T, Wanatabe S, Ogawa S, Fujii C. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: a randomized, double-blind, vehicle-controlled study. J Dermatol. 2022;49(1):86–94.
CAS PubMed Article Google Scholar
Kirsch B, Smith S, Cohen J, DuBois J, Green L, Baumann L, et al. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020;82(6):1321–7.
CAS PubMed Article Google Scholar
Yokozeki H, Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(3):279–88.
留言 (0)